Table 2.
Changes in gene expression in TAMs after bevacizumab monotherapy measured using qPCR
| Gene | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
|---|---|---|---|---|---|---|---|---|
| SDF1α | 0.87 | 45 | 1.4 | 0.095 | 1.4 | 0.87 | 2 | 0.0062 |
| CXCR4 | 0.35 | 16 | 0.13 | 1.7 | >56 | 0.35 | 1.4 | 0.045 |
| NRP1 | 1.3 | 2.6 | 2.1 | 1.1 | 120 | 590 | 2.1 | 4.9 |
| ANG1 | 0.28 | 0.095 | 0.22 | 0.29 | 0.15 | 0.35 | 0.38 | 0.11 |
| ANG2 | 0.037 | 0.12 | 1.3 | 0.5 | 0.22 | 8 | 0.22 | 0.095 |
| DLL4 | 0.81 | 1.1 | 49 | 0.077 | 0.067 | 0.067 | 1.3 | 0.33 |
| PlGF | 0.25 | 9,400 | 1 | 0.0008 | —* | 28 | 13 | 0.37 |
| CXCL5 | 0.077 | 2.7 | 0.095 | 84 | 1.9 | 0.35 | 12 | 0.57 |
| CXCL6 | 0.0003 | 0.011 | 4 | 52 | 1.7 | 150 | 4.9 | 0.54 |
| GM-CSF | 0.57 | 1.1 | 1.6 | 3.5 | 1.1 | 0.0055 | 4.3 | 0.19 |
| IL-8 | 1.1 | 2.6 | 0.38 | 1.1 | 370 | 1.1 | 7.5 | 0.02 |
| TGFβ1 | 0.0024 | 4 | 1 | 0.62 | 10 | 49 | 0.2 | 0.0049 |
| MIF | 0.082 | 2.1 | 680 | 0.47 | 0.054 | 0.0068 | 1.5 | 0.57 |
| NRP2 | 0.22 | 1.1 | 1.6 | 8.6 | 0.31 | 21 | 13 | 0.37 |
| VEGF | 2.6 | 42 | —* | 1.1 | 200 | 0.29 | 15 | 0.009 |
NOTE: Data are shown in fold difference at day 12 after bevacizumab treatment compared with baseline (red, up-regulated >2-fold; white, changed <2-fold; green, down-regulated >2-fold), and normalized to the expression of a housekeeping gene (GAPDH).
*
Gene expression undetectable at both time points.